Brown Advisory International Value Select ETF
Brown Advisory International Value Select ETF (BAIV) is an actively managed, value‑oriented equity fund that delivers concentrated, high‑conviction exposure to publicly traded companies located outside the United States. Operating in a “Size and Style” framework focused on the Total Market, BAIV is not limited to a single market‑cap segment; instead it seeks undervalued opportunities across the full spectrum of international large, mid and small caps, concentrating holdings where the team’s conviction is highest. The strategy combines traditional fundamental research—company financials, competitive positioning and management quality—with AI‑driven analytics to surface mispriced securities and refine portfolio construction and risk controls. That hybrid approach aims to capture long‑term capital appreciation from secular and cyclical value opportunities that passive benchmarks can overlook. BAIV is designed to complement U.S. equity allocations with a targeted international value niche, but investors should expect greater idiosyncratic and country/currency risk due to its concentrated, ex‑U.S. orientation.
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi’s Phase 3 study, officially titled “A Phase 3 Extension Study to Investigate Long-term Safety and Tolerability
| Name | Weight % |
|---|---|
| ICLRIcon Plc | 4.68% |
| MICCMagnum Ice Cream Co. N.V. | 3.74% |
| ADENAdecco Group | 3.46% |
| BNRBrenntag AG (UK) | 3.46% |
| RANDRandstad Holding NV | 3.17% |
| EDENEDENRED SA | 3.15% |
| WKLWolters Kluwer N.V. | 2.67% |
| WPPWPP plc (UK) | 2.65% |
| SNYSanofi SA | 2.64% |
| LANDLand Securities Group Plc R.E.I.T | 2.48% |
| Total | 32.11% |
